Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer

  • Technology appraisal guidance
  • TA285
  • Published: 
Download guidance (PDF)

5 Implementation

5.1 NICE has developed tools to help organisations put this guidance into practice (listed below). These are available on our website.

  • A costing statement explaining the resource impact of this guidance.